Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

2015;55(2):1-10. Surveys performed in 2009 indicated that >80% of retina specialists used topical antibiotics either before and/or after IVT injections. More recent surveys, however, have ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

The study confirmed that Afqlir has equivalent efficacy and comparable safety to its reference medicine, Eylea.

Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...

Diabetic retinopathy (DR) is the primary cause of visual impairment among working-age populations in industrialized nations.

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

The rapid growth in IVT injections has resulted from the introduction of novel drug therapies. In 2004, only 2 agents were specifically approved by the United States Food and Drug Administration ...

The approval boosts the company's biosimilar portfolio. Afqlir's 2mg vial kit and pre-filled syringe for intravitreal injection will combat blindness associated with neovascular age-related ...